VDA 1102

Drug Profile

VDA 1102

Alternative Names: VDA-1102

Latest Information Update: 19 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VidacPharma
  • Class Antineoplastics; Skin disorder therapies; Small molecules
  • Mechanism of Action Hexokinase inhibitors; Keratinocyte modulators; Voltage-dependent anion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Actinic keratosis
  • Preclinical Cutaneous T cell lymphoma; Solid tumours; Squamous cell cancer

Most Recent Events

  • 12 Oct 2017 Efficacy and adverse events data from a phase IIa trial in Actinic keratosis released by VidacPharma
  • 12 Oct 2017 VidacPharma plans a phase IIb trial for Actinitic keratosis in 2018
  • 01 May 2017 VidacPharma completes a phase II trial in Actinic keratosis in USA and Israel (NCT02844777)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top